Table 2.
Clinical, pathological features, treatment and response for chemotherapy of WHO-NEC patients
| Case | Age/sex | Location | Size (mm) | ENETS stage | Tissue sampling | Histology | Ki67 LI (%) | CGA | Synaptophysin | Rb | KRAS | Treatment | Response for platinum-based regimen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 30, M | Body | 45 | IIb | Biopsy and surgical resection | WDNEC | 40 | Positive | Positive | Positive | WT | Operation | ND |
| 2 | 59, F | Body | 30 | IIIb | Biopsy and surgical resection | PDNEC (small cell) | 80 | Positive | Positive | Positive | MT | Operation | ND |
| 3 | 49, F | Body | 35 | IV | Biopsy | PDNEC (large cell) | 85 | Positive | Positive | Negative | MT | CT (Gemcitabine) | ND |
| 4 | 68, F | Tail | 36 | IV | Biopsy | WDNEC | 48 | Positive | Positive | Positive | WT | CT (IP) | PD |
| 5 | 63, F | Body | 33 | IV | Biopsy | PDNEC (large cell) | 54 | Positive | Positive | Negative | MT | CT (IP) | PR |
| 6 | 61, M | Body | 45 | IV | Biopsy | PDNEC (large cell) | 90 | Positive | Positive | Negative | MT | CT (EP) | PR |
| 7 | 74, M | Head | 20 | IV | Biopsy | PDNEC (small cell) | 90 | Positive | Positive | Negative | WT | BSC | ND |
| 8 | 37, M | Head | 20 | IV | Biopsy | PDNEC (small cell) | 80 | Positive | Positive | Negative | MT | CT (EP) | PR |
| 9 | 50, F | Tail | 35 | IV | Biopsy | WDNEC | 45 | Negative | Positive | Positive | WT | CT (Everolimus) | ND |
| 10 | 55, M | Tail | 30 | IV | Biopsy | WDNEC | 53 | Positive | Positive | Positive | WT | CT (EP) | PD |
| 11 | 66, M | Tail | 70 | IV | Biopsy | PDNEC (small cell) | 95 | Positive | Positive | Negative | MT | CT (IP) | PR |
CGA chromogranin A, WT wild type, MT mutant, CT chemotherapy, IP cisplatin + irinotecan, EP cisplatin + etoposide, BSC best supportive care, ND not done, PD progressive disease, PR partial response